{"nctId":"NCT02706847","briefTitle":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","startDateStruct":{"date":"2016-03-15","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":499,"armGroups":[{"label":"Upadacitinib 15 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Upadacitinib"]},{"label":"Upadacitinib 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Upadacitinib"]},{"label":"Placebo / Upadacitnib 15 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Upadacitinib"]},{"label":"Placebo / Upadacitnib 30 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Upadacitinib"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Upadacitinib","otherNames":["ABT-494","RINVOQ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of rheumatoid arthritis (RA) for≥ 3 months.\n* Treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration prior to the first dose of study drug.\n* Participant has been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide. A combination of up to two background csDMARDs is allowed except the combination of MTX and leflunomide.\n* Meets both of the following criteria:\n* ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.\n* hsCRP ≥ 3mg/L at Screening Visit.\n\nExclusion Criteria:\n\n* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).\n* History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia \\[currently with active symptoms\\]). Current diagnosis of secondary Sjogren's Syndrome is permitted.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12","description":"The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:\n\n1. ≥ 20% improvement in 68-tender joint count;\n2. ≥ 20% improvement in 66-swollen joint count; and\n3. ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity\n   * Patient global assessment of disease activity\n   * Patient assessment of pain\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI)\n   * High-sensitivity C-reactive protein (hsCRP).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"64.6","spread":null},{"groupId":"OG002","value":"56.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12","description":"The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12.\n\nThe DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.\n\nA DAS28 score less than or equal to 3.2 indicates low disease activity.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"43.3","spread":null},{"groupId":"OG002","value":"42.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12","description":"The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":null},{"groupId":"OG001","value":"-2.31","spread":null},{"groupId":"OG002","value":"-2.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12","description":"The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.\n\nA negative change from Baseline in the overall score indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":null},{"groupId":"OG001","value":"-0.39","spread":null},{"groupId":"OG002","value":"-0.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12","description":"The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).\n\nThe physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":null},{"groupId":"OG001","value":"5.83","spread":null},{"groupId":"OG002","value":"7.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12","description":"Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:\n\n1. ≥ 50% improvement in 68-tender joint count;\n2. ≥ 50% improvement in 66-swollen joint count; and\n3. ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity\n   * Patient global assessment of disease activity\n   * Patient assessment of pain\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI)\n   * High-sensitivity C-reactive protein (hsCRP).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"34.1","spread":null},{"groupId":"OG002","value":"35.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12","description":"Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:\n\n1. ≥ 70% improvement in 68-tender joint count;\n2. ≥ 70% improvement in 66-swollen joint count; and\n3. ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity\n   * Patient global assessment of disease activity\n   * Patient assessment of pain\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI)\n   * High-sensitivity C-reactive protein (hsCRP).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"11.6","spread":null},{"groupId":"OG002","value":"23.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1","description":"Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:\n\n1. ≥ 20% improvement in 68-tender joint count;\n2. ≥ 20% improvement in 66-swollen joint count; and\n3. ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity\n   * Patient global assessment of disease activity\n   * Patient assessment of pain\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI)\n   * High-sensitivity C-reactive protein (hsCRP).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"27.4","spread":null},{"groupId":"OG002","value":"24.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":169},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Rheumatoid arthritis","Nasopharyngitis","Bronchitis"]}}}